🚨Get access to our latest update on HTA in Germany by Ecker + Ecker and Canada by MORSE Consulting Inc.📝 register here to receive the latest and upcoming issues of our Access Briefing: https://forms.office.com/e/Jt8bPmVkdJ📥

All resolutions by G-BA for HTA procedures of pharmaceuticals published in the first quarter of 2025:

Our highlights in a nutshell:

🏛️ 32 resolutions published by G-BA

🔝 Alectinib: Hint for major additional benefit for one subpopulation (highest category)

❌ Two assessments without dossier led to inclusion into existing reference price groups; one involved an orphan drug under the orphan privilege

⚠️ One assessment for antibiotic of last resort

🚫  Sotatercept: Orphan privilege waived by company for initial full assessment

🔁 Pembrolizumab: 35th assessment

🧬 Polihexanid: Assessment as known substance but under orphan status

 

The stats:

⭐ Major additional benefit: 1 (3%)

👍 Considerable additional benefit: 4 (13%)

👌 Minor additional benefit: 6 (19%)

🙆 Non quantifiable benefit: 5 (16%)

❌ No additional benefit proven: 15 (47%)

✅ Additional benefit considered proven: 1 (3%)

  

We are happy to share resolutions by Canada’s Drug Agency (CDA-AMC) from our partner MORSE Consulting Inc. as well:

 

Highlight:

⏳️ CDA-AMC issued a draft time-limited reimbursement (TLR) recommendation for Enhertu, the 2nd TLR ever issued after Epkinly. TLR recommendation is a new CDA-AMC review process whereby a temporary recommendation is issued based on a phase II clinical data assessment, and the final recommendation is contingent upon a future reassessment of additional evidence (i.e., phase III clinical data).

 

The stats:

✅ 14 Final Conditional Reimbursement

✔️ 6 Draft Conditional Reimbursement

⏳️ 1 Time-Limited Reimbursement

❌ 2 Do Not Reimburse

 

Market Access is local 🌍We offer a One Stop Shop for Europe: Together with our partner companies we cover all key European markets. 250 local Market Access experts from our network of partner companies follow one common methodology.